Blueprint Medicines Corp (NASDAQ: BPMC) has recently experienced extremely important negative changes in investment behavior: negative upside/downside volume developed, its shorter term price trend turned down, and the stock fell on very heavy volume.
Marginal negative changes in fundamentals have recently occurred for Blueprint Medicines Corp (NASDAQ: BPMC): significant quarterly earnings deceleration occurred.
In light of these highly negative signals we are reviewing our current Overall Rating of C. We would view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, BPMC is expected to be a modest Value Builder.
Blueprint Medicines has a current Value Trend Rating of C (Low Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Blueprint Medicines has a very low Appreciation Score of 1 but a very high Power Rating of 93, producing the Low Neutral Value Trend Rating.
Recent Price Action
Blueprint Medicines Corp (NASDAQ: BPMC) stock closed at $92.97 on 8/5/24 after a decline of -3.9%. Moreover, exceptionally high trading volume at 221% of normal accompanied the decline. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -17.1% during the last week.
Be the first to comment